Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.99 USD
−32.96 M USD
65.42 M USD
13.72 M
About Neuropace, Inc.
Sector
Industry
CEO
Joel D. Becker
Website
Headquarters
Mountain View
Founded
1997
FIGI
BBG001KWZD52
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NPCE is 11.19 USD — it has increased by 5.67% in the past 24 hours. Watch Neuropace, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Neuropace, Inc. stocks are traded under the ticker NPCE.
NPCE stock has risen by 11.81% compared to the previous week, the month change is a 82.70% rise, over the last year Neuropace, Inc. has showed a 39.87% increase.
We've gathered analysts' opinions on Neuropace, Inc. future price: according to them, NPCE price has a max estimate of 20.00 USD and a min estimate of 9.00 USD. Watch NPCE chart and read a more detailed Neuropace, Inc. stock forecast: see what analysts think of Neuropace, Inc. and suggest that you do with its stocks.
NPCE reached its all-time high on Apr 27, 2021 with the price of 27.38 USD, and its all-time low was 1.22 USD and was reached on Dec 28, 2022. View more price dynamics on NPCE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NPCE stock is 11.50% volatile and has beta coefficient of 0.69. Track Neuropace, Inc. stock price on the chart and check out the list of the most volatile stocks — is Neuropace, Inc. there?
Today Neuropace, Inc. has the market capitalization of 356.09 M, it has decreased by −5.06% over the last week.
Yes, you can track Neuropace, Inc. financials in yearly and quarterly reports right on TradingView.
Neuropace, Inc. is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
NPCE earnings for the last quarter are −0.19 USD per share, whereas the estimation was −0.27 USD resulting in a 29.26% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Neuropace, Inc. earnings.
Neuropace, Inc. revenue for the last quarter amounts to 21.06 M USD, despite the estimated figure of 19.07 M USD. In the next quarter, revenue is expected to reach 20.91 M USD.
NPCE net income for the last quarter is −5.45 M USD, while the quarter before that showed −7.51 M USD of net income which accounts for 27.44% change. Track more Neuropace, Inc. financial stats to get the full picture.
No, NPCE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 5, 2024, the company has 171.00 employees. See our rating of the largest employees — is Neuropace, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Neuropace, Inc. EBITDA is −21.34 M USD, and current EBITDA margin is −39.08%. See more stats in Neuropace, Inc. financial statements.
Like other stocks, NPCE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neuropace, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Neuropace, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Neuropace, Inc. stock shows the buy signal. See more of Neuropace, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.